The Technical Analyst
Timber Pharmaceuticals [TMBR]
Exchange: AMEX Industry: Biotechnology
Timber Pharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.74% $0.343
America/New_York / 28 nov 2023 @ 15:59
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1.176 mill |
| EPS: | -1.970 |
| P/E: | -0.174 |
| Earnings Date: | Dec 04, 2023 |
| SharesOutstanding: | 3.43 mill |
| Avg Daily Volume: | 0.108 mill |
| RATING 2023-12-26 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Neutral | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 1/22 | 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | |
| Gr.Profit | n/a | n/a | n/a | |||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.174 | sector: PE 12.30 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -0.174 | industry: PE -5.55 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ -0.205 - 0.225 ( +/- 2 128.71%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-08-20 | Koconis John | Buy | 70 385 | Common Stock, par value $0.001 per share |
| 2023-08-20 | Mendelsohn Alan | Buy | 35 193 | Common Stock, par value $0.001 per share |
| 2023-08-20 | Lucchese Joseph | Buy | 35 193 | Common Stock, par value $0.001 |
| 2023-04-15 | Koconis John | Buy | 45 010 | Stock Option (right to buy) |
| 2023-04-15 | Gaal Lubor | Buy | 4 100 | Common Stock, par value $0.001 per share |
| INSIDER POWER |
|---|
| 100.00 |
| Last 85 transactions |
| Buy: 16 585 051 | Sell: 6 873 671 |
Forecast:
01:40 - $0.988
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.343 (0.74% ) |
| Volume | 0.130 mill |
| Avg. Vol. | 0.108 mill |
| % of Avg. Vol | 120.91 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For TMBR
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
TMBR
Timber Pharmaceuticals LLC, a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for orphan dermatologic diseases. The company's lead product candidates include TMB-001, a patented topical formulation of isotretinoin that has completed Phase 2b clinical trial for the treatment of moderate to severe subtypes of CI, a group of rare genetic keratinization disorders; and TMB-002, a proprietary topical formulation of rapamycin, which is in Phase 2b clinical trial for the treatment of facial angiofibroma in tuberous sclerosis complex, a multisystem genetic disorder resulting in the growth of hamartomas in multiple organs. It is also involved in the development of TMB-003, a proprietary formulation of Sitaxsentan, which is a selective endothelin-A receptor antagonist that is in preclinical development for the treatment of sclerotic skin diseases. In addition, the company engages in the development of BPX-01, which is in Phase 3 topical minocycline for the treatment of inflammatory lesions of acne vulgaris; and BPX-04 that is a Phase 3 ready topical minocycline for the treatment of papulopustular rosacea. It has license agreement with AFT Pharmaceuticals Limited. The company was founded in 2019 and is headquartered in Basking Ridge, New Jersey.
Latest Press Releases
2024-03-10 18:15:00 - Press Release
Timber Pharmaceuticals, Inc., A Leo Pharma Company, Presents Late-breaking Preliminary Results Of Tmb-001 In Moderate-to-severe Congenital Ichthyosis (ci) At The 2024 Aad Annual Meeting
Madison, n.j.--(business wire)--timber pharmaceuticals, inc., a leo pharma comp., presents late-breaking preliminary results of tmb-001 in moderate-to-severe congenital ichthyosis ci.
2024-01-23 06:30:00 - Press Release
Leo Pharma Finalizes Acquisition Of Key Assets From Timber Pharmaceuticals
Ballerup, denmark--(business wire)--leo pharma today announced that it has finalized the acquisition of the strategic asset tmb-001 as well as certain other assets from timber pharmaceuticals following its chapter 11 bankruptcy filing. the tmb-001 project aims to develop a topical treatment for multiple moderate to severe subtypes of congenital ichthyosis – a skin disease with significant unmet need and no approved prescription therapies available. the tmb-001 project continues as planned and w.
2023-11-29 17:59:49 - Press Release
Timber Pharmaceuticals Announces Commencement Of Nyse American Delisting Proceedings: Common Stock Expected To Begin Trading On The Otc Market
Warren, n.j., nov. 29, 2023 — timber pharmaceuticals, inc.
2023-11-29 17:26:00 - Press Release
Timber Pharmaceuticals Announces Commencement Of Nyse American Delisting Proceedings: Common Stock Expected To Begin Trading On The Otc Market
Warren, n.j., nov. 29, 2023 (globe newswire) -- timber pharmaceuticals, inc. ("timber" or the "company") (nyse american: tmbr), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that the staff of nyse regulation (the “nyse regulation”) has determined to immediately suspend trading in the company's common stock from nyse american, llc (the “nyse american”).
2023-11-28 17:21:00 - Press Release
Timber Pharmaceuticals Receives Court Approval Of All “first Day” Motions To Support Business Operations & Discloses Communication From Nyse American
Warren, nj, nov. 28, 2023 (globe newswire) -- via newmediawire – timber pharmaceuticals, inc. (nyse american: tmbr), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, and its affiliated debtors and debtor-in-possession ("timber" or the "company"), today announced that all "first day" motions related to the company's voluntary chapter 11 petitions for reorganization filed on november 17, 2023, were approved on an interim basis by the u.s. bankruptcy court for the district of delaware.
Latest News
2023-08-22 11:17:23 - Zacks Investment Research
Timber (TMBR) to Get Acquired by LEO Pharma for $36M, Stock Up
2023-08-21 10:58:32 - InvestorPlace
Why Is Timber Pharmaceuticals (TMBR) Stock Up 96% Today?
Timber Pharmaceuticals (NYSEMKT: TMBR ) stock is undergoing a massive rally on Monday after announcing that Leo US is acquiring it in a $36 million deal. According to a press release from Timber Pharmaceuticals, that acquisition has an upfront payment of $14 million for TMBR stock.
2023-06-08 12:53:04 - Zacks Investment Research
Timber (TMBR) Surges on Carcinogenicity Waiver for TMB-001
Timber (TMBR) receives a dermal carcinogenicity waiver from the FDA for TMB-001, which is being developed to treat moderate-to-severe subtypes of congenital ichthyosis.
2023-04-14 11:26:24 - Zacks Investment Research
Bears are Losing Control Over Timber Pharmaceuticals, Inc. (TMBR), Here's Why It's a 'Buy' Now
Timber Pharmaceuticals, Inc. (TMBR) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
2023-02-27 06:00:00 - PennyStocks
Building a Penny Stocks Portfolio For Long Term
Use these tips for buying penny stocks for the long term The post Building a Penny Stocks Portfolio For Long Term appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2023-02-26 11:10:00 - PennyStocks
Penny Stock Investing: How to Analyze Market Conditions
Use these tips to analyze penny stocks The post Penny Stock Investing: How to Analyze Market Conditions appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2023-02-24 11:57:14 - InvestorPlace
Why Is Timber Pharmaceuticals (TMBR) Stock Up 61% Today?
Timber Pharmaceuticals (NYSEMKT: TMBR ) stock is taking off on Friday after getting an orphan drug designation in Europe. That comes from the EC and covers TMB-001 for the treatment of X-linked recessive ichthyosis.
2022-08-25 11:51:12 - PennyStocks
Top Penny Stocks To Buy? 4 For Your Watch List Before Next Week
2022-08-10 06:00:00 - PennyStocks
Best Penny Stocks to Buy Now? 3 For Your August List
Here's what you need to know about trading penny stocks on August 10th The post Best Penny Stocks to Buy Now? 3 For Your August List appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-04-28 15:59:01 - PennyStocks
Best Penny Stocks to Buy Under $1? 3 to Watch as April Ends
Are these under $1 penny stocks on your watchlist? The post Best Penny Stocks to Buy Under $1?